Imfinzi EV bladder cancer combinations have achieved a historic milestone in the treatment of muscle-invasive disease. AstraZeneca today announced high-level results from the Phase III VOLGA trial, demonstrating that the perioperative use of Imfinzi (durvalumab) plus neoadjuvant enfortumab vedotin (EV) significantly improves survival outcomes. This breakthrough is particularly significant for patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy, a group that has long faced limited curative-intent options.
Historic Survival Gains for Imfinzi EV Bladder Cancer Patients
The VOLGA trial results represent a paradigm shift in oncology. According to the planned interim analysis, the Imfinzi EV bladder cancer regimen demonstrated statistically significant and clinically meaningful improvements in both Event-Free Survival (EFS) and Overall Survival (OS) compared to the standard of care. Patients in the comparator arm underwent radical cystectomy (surgery to remove the bladder) with or without approved adjuvant treatments.
For the first time, a perioperative immunotherapy-based combination has shown a definitive OS benefit in this specific patient population. By integrating Imfinzi EV bladder cancer therapy into the early stages of treatment, both before and after surgery, clinicians can now offer a more robust defense against disease recurrence and progression.
Analyzing the VOLGA Trial: A New Standard for Imfinzi EV Bladder Cancer
The Phase III VOLGA trial is a randomized, open-label, multi-center global study. It evaluated the efficacy of perioperative Imfinzi with or without Imjudo (tremelimumab) in combination with neoadjuvant enfortumab vedotin.
Key clinical findings include:
- Efficacy in Arm 2: The combination of Imfinzi EV bladder cancer therapy met the dual primary endpoints of EFS and a key secondary endpoint of OS.
- Impact of Arm 1: The triplet combination (Imfinzi + Imjudo + EV) showed a statistically significant EFS improvement and a favorable trend in OS, which will be reassessed in future analyses.
- Safety and Tolerability: The safety profile of the Imfinzi EV bladder cancer regimen was consistent with the known profiles of the individual medicines, with no new safety signals identified.
Up to half of patients with muscle-invasive bladder cancer are not eligible for cisplatin and face high rates of disease recurrence,
The VOLGA results show that perioperative durvalumab significantly extends survival when combined with neoadjuvant enfortumab vedotin.
Thomas Powles
The Growing Impact of Imfinzi EV Bladder Cancer Therapy
Bladder cancer is the 9th most common cancer globally, with over 614,000 new cases diagnosed annually. While radical cystectomy is a standard surgical intervention, nearly 50% of MIBC patients experience recurrence post-surgery. The introduction of the Imfinzi EV bladder cancer treatment protocol addresses a critical unmet need for those unable to receive traditional chemotherapy.
AstraZeneca’s commitment to redefining cancer care is evident through its broader clinical program. This includes the NIAGARA trial, which established Imfinzi in cisplatin-eligible settings, and the POTOMAC trial for non-muscle-invasive disease. To explore further oncology research and guidelines, visit the European Association of Urology (EAU) or the American Cancer Society.
VOLGA Phase III Trial Specifications
| Data Point | Value |
| Focus Keyword | Imfinzi EV bladder cancer |
| Trial Status | Phase III, Positive High-Level Results |
| Patient Population | MIBC (Cisplatin-Ineligible or Declined) |
| Total Participants | 695 |
| Primary Endpoints | Event-Free Survival (EFS) |
| Key Secondary Endpoints | Overall Survival (OS), pCR, DFS |
Survival Outcomes Summary
| Treatment Arm | Endpoint: EFS | Endpoint: OS |
| Imfinzi + EV (Perioperative) | Statistically Significant Improvement | Statistically Significant Improvement |
| Imfinzi + Imjudo + EV | Statistically Significant Improvement | Favourable Trend (Not yet significant) |
| Standard of Care | Baseline | Baseline |
